



## **GlycoMimetics to Present at the Piper Jaffrey 31st Annual Healthcare Conference 2019**

November 29, 2019

ROCKVILLE, Md.--(BUSINESS WIRE)--Nov. 29, 2019-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the Piper Jaffrey 31<sup>st</sup> Annual Healthcare Conference in New York, New York, which takes place on December 3, 2019. Ms. King's presentation is scheduled for 1:30 p.m. ET.

To access the live webcast and subsequent archived recordings for this presentation, please visit the GlycoMimetics website at [www.glycomimetics.com](http://www.glycomimetics.com).

### **About GlycoMimetics, Inc.**

GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' wholly-owned drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including a Company-sponsored Phase 3 trial in relapsed/refractory AML. GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at [www.glycomimetics.com](http://www.glycomimetics.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191129005249/en/>

Source: GlycoMimetics

### **Investor Contact:**

Shari Annes

Phone: 650-888-0902

Email: [sannes@annesassociates.com](mailto:sannes@annesassociates.com)

### **Media Contact:**

Jamie Lacey-Moreira

Phone: 410-299-3310

Email: [jamielacey@presscommpr.com](mailto:jamielacey@presscommpr.com)